FDA Approves Novel Gene Therapy for Rare Form of Vision Loss FDA Approves Novel Gene Therapy for Rare Form of Vision Loss
Luxturna is for children and adults with a form of inherited vision loss that may lead to blindness. It is the first gene therapy approved in the United States to treat a disease caused by mutations in a specific gene.FDA Approvals
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
More News: Blindness | Children | Eyes | Gene Therapy | Genetics | Health | Opthalmology | USA Health